asunaprevir Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Asunaprevir is an experimental drug candidate for the treatment of hepatitis C. It was undergoing development by Bristol-Myers Squibb and has completed Phase III clinical trials in 2013.   Wikipedia

Chemistry

  • SMILES: COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C4CC4)c5cc(Cl)ccc15
  • InChIKey: XRWSZZJLZRKHHD-WVWIJVSJSA-N
  • Mol. Mass: 748.3
  • ALogP: 3.85
  • ChEMBL Molecule:
    asunaprevir  
More Chemistry

Pharmacology

Alternative names

asunaprevir | bms-650032 | sunvepra

Organizations (37)

Research & Development (37)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (7)

Approved Indications (1)


 

Hepatitis C

Experimental Indications - Clinical Trial Phases 1-4 (7)


 

Fibrosis (Phase 2)

Hepacivirus (Phase 3)

Hepatic Insufficiency (Phase 1)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 4)

HIV Infections (Phase 2)

Osteoarthritis, Hip (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 44
  • # of Trial Organizations: 37

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue